Serial cfDNA analyses may also be useful to evaluate changes in differentiation state and active histone marks that occur on EZH2 therapy, with downregulation of AR activity expected after EZH2 inhibition in castration-resistant PRAD, upregulation of AR and downregulation of NE programs in mixed/transition tumors, and upregulation of NE programs in NEPC. This evidence concerns the gene EZH2 and prostate adenocarcinoma.